nach oben

Erschienen in:

01.11.2013 | Original Paper

Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents

verfasst von: Yazdan Seivani, Mohamed Abdel-Wahab, Volker Geist, Gert Richardt, Dmitriy S. Sulimov, Mohamed El-Mawardy, Ralph Toelg, Ibrahim Akin

Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The optimal antithrombotic treatment for patients on oral anticoagulants (OAC) undergoing percutaneous coronary intervention (PCI) is controversial. We analyzed the safety and efficacy of dual therapy with OAC plus clopidogrel in atrial fibrillation (AF) patients receiving drug-eluting stents (DES).

Methods and results

In this retrospective analysis, all AF patients treated with dual therapy were retrospectively identified. Efficacy endpoints included cardiac death, myocardial infarction (MI), stent thrombosis (ST) and cerebrovascular stroke at follow-up, while safety was assessed by bleeding events defined by the Bleeding Academic Research Consortium (BARC). Between January 2008 and August 2010, 221 patients with high-risk AF received a DES and a dual therapy with OAC and clopidogrel. At a mean follow-up of 19 months, bleeding complications occurred in 22 patients (10 %), more than half of them (n = 12) were related to the index PCI. We observed 11 cardiac deaths (4.9 %), 9 MIs (4.1 %), 3 definite (1.4 %) and no probable ST at follow-up. All definite ST occurred after cessation of clopidogrel at 8, 22, and 30 months after PCI in patients not adequately anticoagulated. Eight patients (3.6 %) had an ischemic stroke, five of which after temporary or permanent cessation of OAC.

Conclusion

The data generated from this large single-center experience in AF patients treated with DES revealed that dual therapy with OAC plus clopidogrel for 6–12 months followed by monotherapy with OAC appears both safe and effective at long-term follow-up. However, after clopidogrel cessation, maintaining therapeutic anticoagulation with an INR >2 is essential to prevent both thrombotic and embolic events.

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: an anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRef

Alexander KP, Galanos AN, Jollis JG, Stafford JA, Peterson ED (2001) Post-myocardial infarction risk stratification in elderly patients. Am Heart J 142:37–42PubMedCrossRef

Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith Sc Jr, Peterson ED, Becker RC (2008) Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 155:361–368PubMedCrossRef

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothou BK, Ting HH, ACCF, AHA, SCAI (2011) 2011 ACCF/AHA/SCAI Guideline for perctaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–e122PubMedCrossRef

Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamago JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367PubMedCrossRef

Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GY (2008) Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51:818–825PubMedCrossRef

Karjalainen PP, Porela P, Ylitalo A, Vikman K, Vaittinen MA, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28:726–732PubMedCrossRef

Denas G, Padayattil Jose S, Gresele P, Erba N, Testa S, De Micheli V, Quintavalla R, Poli D, Bracco A, Fierro T, Iliceto S, Penga V (2013) Major bleeding in patients undergoing PCI and triple or duale antithrombotic therapy: a parallel-cohort study. J Thromb Thrombolysis 35:178–184PubMedCrossRef

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van ES GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef

10.

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgmigli M, Vranckx P, Taggert D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747PubMedCrossRef

11.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef

12.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef

13.

Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werft F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB (2009) Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30:2019–2028PubMedCrossRef

14.

Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW (2011) Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZON-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 58:1750–1756PubMedCrossRef

15.

Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368PubMedCrossRef

16.

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marin F, Consesnus Document of European Society of Cardiology Working Group on Thrombosis (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 31:1311–1318PubMedCrossRef

17.

Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolollo DJ (2011) Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv 4:522–534PubMedCrossRef

18.

Airaksinen KE, Suurmunne H, Porela P, Niemelä M, Vikman S, Puurunen M, Annala AP, Biancari F, Karlajainen PP (2010) Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol 106:175–179PubMedCrossRef

19.

Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S for the ACTIVE Writing Group of the ACTIVE Investigators (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912PubMedCrossRef

20.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators (2006) Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 152:967–973PubMedCrossRef

21.

Mehilli J Intracoronary stenting and antithrombotic regimen: testing of a six-week versus a six-month clopidogrel treatment regimen in patients with concomitant aspirin and oral anticoagulation therapy following drug-eluting stenting (ISAR-Triple). Clinicaltrials.gov NCT00776633

22.

Sambola A Test of efficacy and safety of the dual antiplatelet therapy compared to the combination of oral anticoagulant therapy + dual antiplatelet therapy in patients with atrial fibrillation with low-moderate risk submitted to coronary stent implantation. Clinicaltrials.gov NCT01141153

23.

Dewilde W, Oirbans T, Verheugt F, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heertermans AA, Vis MM, Tijsen JG, van`t Hof AW, Ten Berg JM, WOEST Study Investigators (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115PubMedCrossRef

24.

Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR (2009) Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 157:132–140PubMedCrossRef

25.

Loncoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863CrossRef

26.

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216PubMedCrossRef

27.

Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Schöller R, Zahn R, Diller F, Darius H, Dill T, Huber K (2011) Efficacy and safety of a high loading dose of clopidogrel administration prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312PubMedCrossRef

28.

Zahn R, Neumann FJ, Büttner HJ, Richardt G, Schneider S, Levenson B, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Hamm CW (2012) Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clin Res Cardiol 101:709–716PubMedCrossRef

29.

Cuneo A, Bramlage P, Hochadel M, Senges J, Nienaber C, Kuck KH, Tebbe U (2012) Concurrent drug-eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. Clin Res Cardiol 101:281–288PubMedCrossRef

30.

Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA (2013) Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol 102:371–381PubMedCrossRef

31.

Gilard M, Blachard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le Breton H, Bochat J, STENTICO Investigators (2009) Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting [from stenting and oral anticoagulants (STENTICO)]. Am J Cardiol 104:338–342PubMedCrossRef

32.

Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schömig A (2010) Oral anticoagulation with coumarin derivates and antiplatelet effects of clopidogrel. Eur Heart J 31:1205–1211PubMedCrossRef

33.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themelses E, Varrone J, Wang S, Slings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin LM, RE-LY Steering Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef

34.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Senson JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992PubMedCrossRef

35.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef

36.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators, (2007) Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 357:2001–2015PubMedCrossRef

37.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef

Titel: Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents
verfasst von: Yazdan Seivani
Mohamed Abdel-Wahab
Volker Geist
Gert Richardt
Dmitriy S. Sulimov
Mohamed El-Mawardy
Ralph Toelg
Ibrahim Akin
Publikationsdatum: 01.11.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 11/2013
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0592-z

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents